Impact Biomedical Inc., a wholly owned subsidiary of Document
Security Systems Inc. (NYSE American: DSS), today announced updates
to several of its key research projects, including key
collaborations, breakthroughs in treatment protocols and potential
global licensing opportunities as a way to begin planning the next
phase of its research agenda and position itself as a global leader
in the future of biotech.
Mr. Chan Heng Fai, Chairman of Document Security Systems, said
“All of these products show DSS’ commitment to innovation and a
stronger future to practical biotechnology that helps all
people.”
Working with its advanced scientific research unit, Global
Research & Discovery Group Sciences (GRDG), Impact Biomedical
Inc. has laid the groundwork for a future that is focused on
scientifically-tested, high-impact solutions to global problems
that humans face across the world. “Each of these products — from
antibiotics to food preservation to creating new ways to develop
medicines — are on the cutting edge of biotechnology and will
provide a strong foundation for future discoveries through Impact
Biomedical and GRDG that are designed to make the world safer, help
people have better quality of life, and raise the bar for what is
possible,” said Frank Heuszel, the President of Impact Biomedical,
Inc.
Impact Biomedical will continue to drive mission-oriented
research and development that advances drug discovery to the next
level with GRDG and Daryl Thompson as the lead. “I believe the
research world needs a renaissance where innovation and imagination
are the key to a biotechnical future that will help the global
community face increased biological threats. The research projects
outlined are part of the pathway for Impact Biomedical to become a
significant leader in that respect,” said Daryl Thompson, Impact
Biomedical’s Director of Scientific Initiatives and founder of GRDG
Sciences, LLC.
Dr. Roscoe M. Moore, Jr., GRDG's Chief Scientific Advisor,
United States Assistant Surgeon General (Retired) and former
Epidemic Intelligence Service (EIS) Officer at U.S. Center for
Disease Control and Prevention said that these projects have the
potential to already make a difference in the world. “The project
updates announced by Impact Biomedical, Inc. today offer some of
the most innovative and creative ways to meet needs that people
face every day. It also points us toward new projects that will
keep us active for years to come.”
Research projects:
Impact Biomedical, GRDG Sciences team up with Thomas
Swan & Co.The research collaboration between Impact
Biomedical, Inc., GRDG Sciences and Thomas Swan & Co. will
study Procombin, a plant-based preservation booster agent designed
with the the intention of increasing effectiveness of antibiotics,
preservatives, and other antimicrobials. The research will study
Procombin’s effectiveness for use in multiple applications,
including household, institutional, and personal care products.
CRST-1 research results expected to be published
soonCompleted research on CRST-1, a probe molecule
designed to accompany traditional cancer treatments to increase the
effectiveness of certain cancer medications used is currently being
peer-reviewed by a major U.S. University. According to the
research, it was shown to inhibit PIM 1 and PIM 3 with
IC50s 0.00014 M and 0.00018 M, respectively, in
pre-clinical cell phosphorylation assays. CRST-1 is nontoxic and
has yet shown no adverse side effects. The latest research results
are expected to be published by the end of summer 2021.
Quantum Adjuvants in testing phase take aim at Patent
CliffResearch for Quantum Adjuvants is currently underway,
and data should be available by the end of summer 2021. Quantum
Adjuvants hold the possibility of a new way to make effective drugs
and help de-escalate a looming patent cliff crisis in the
biomedical industry. Quantum Adjuvants may hold a key for
developing new medicines through the development of a new form of
squalene that is more consistent and, possibly, more effective.
Vanexn study nearing completion before determining next
stepsVanexn is a food preservative that, in our early
studies, successfully inhibited proliferation of Aspergillus
Niger, Talaromyces Pinophilus and Candida Albicans. The substance
was discovered by GRDG during previous research in the Florida
Everglades and potentially fills a need for new and more effective
food preservatives. To deploy Vanexn in the food supply, the
current formula is being researched to be positioned in bread and
baked goods to reduce spoilage and improve shelf life.
The current study is nearing completion. The results of the
study will help Impact Biomedical determine the next steps for
Vanexn.
Projects ready for global licensing:
Equivir in discussions for global license in a variety
of productsEquivir is a novel blend of patented FDA
Generally Recognized as Safe (GRAS) eligible polyphenols that have
demonstrated antiviral effects as well as potential applications as
a health supplement or medication. Initial research indicated a
possible effectiveness as an anti-viral agent and to reduce an
inflammatory response.
Equivir functions to block viral infection and subsequent
replication in host cells. Equivir has demonstrated effectiveness
in in-vitro studies inhibiting viral infections and SARS COV2.
Equivir showed to have broad antiviral efficacy against multiple
types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19 within
the studies. Additional research on Equivir’s effectiveness in
causing prophylactic effects in COVID has started.
We are in discussions for a global license of Equivir with
formulations currently being created in a variety of
products.
Linebacker available for global licensing after awarded
recent international patentLinebacker, a patented
therapeutic medication, was issued an international patent in April
2021, which is currently available for global licensing.
Linebacker was created to shadow the Panacea Project, a U.S.
Defense Advanced Research Projects Agency (DARPA) program to
provide novel, multi-target therapeutics for unmet physiological
needs. It has demonstrated compelling pre-clinical results against
SARS and MERS in previous laboratory testing. Linebacker has
demonstrated in-vitro effectiveness in neurological diseases
including Parkinson’s, many types of cancer, and multiple pathogens
such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS,
MERS, Malaria, and Ebola.
Laetose under negotiations for global
licensingLaetose is the focus of a new study being
conducted to better understand the positive effects of the
substance on those with metabolic syndrome and diabetes. It is
derived from a unique patented combination effort to address the
negative impacts of excess sugar intake, and therefore being
investigated to fight obesity and diabetes.
3F Biofragrance open for global licensing and licensing
tech3F Biofragrance was designed for the Open-Air Defense
Initiative, a strategy to protect large numbers of people where
they gather, including containment areas, ports of entry, train
stations, airports, convention centers, offices, schools, and
hospitals. In our research studies, preliminary results show 3F
DEET Booster was significantly more effective than DEET. 3F
Antiviral has shown to be effective against E. coli, MRSA,
Influenza, Rhinovirus, Tuberculosis, and COVID-19. 3F, which was
issued a patent in April 2021, is believed to have applications, in
normal household products such as laundry detergents, in shampoos,
in high-end cosmetics, and in skincare products.
About Impact Biomedical, Inc. Impact
Biomedical, Inc. ("Impact Biomedical") is a wholly owned subsidiary
of DSS. Impact Biomedical strives to leverage its scientific
know-how and intellectual property rights to provide solutions that
have been plaguing the biomedical field for decades. By tapping
into the scientific expertise of GRDG Sciences, LLC, Impact
Biomedical pledges to undertake a concerted effort in the R&D,
drug discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact Biomedical visit
http://impbio.com/.
About Document Security Systems, Inc. DSS is a
multinational company operating businesses focused on brand
protection technology, blockchain security, direct marketing,
healthcare, real estate, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman, Mr. Fai Chan, a highly successful global
business veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
billion.
For more information on DSS visit
http://www.dsssecure.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
Safe Harbor Disclosure This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024